Browse Studies — Arctuva

Phase 1

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unme…

B-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-Cell+12 more

Estimated

~$10 – $8,750

Estrella Immunopharma, Inc.NCT06343311

Phase 1

NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to e…

Lymphoma, Non-Hodgkin'sLymphoma, Diffuse Large B-CellFollicular Lymphoma

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07226843

Phase 2

A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a Complete Response With Upfront Chemoimmunotherapy

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in th…

LymphomaFollicular LymphomaLymphoma,Non-Hodgkin+1 more

Estimated

~$10 – $6,250

Beth Israel Deaconess Medical CenterNCT06510361